Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)
about
Corneal neovascularization and biological therapyPolysaccharide hydrogel combined with mesenchymal stem cells promotes the healing of corneal alkali burn in ratsSuppression of In Vivo Neovascularization by the Loss of TRPV1 in Mouse Cornea.A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery.Nanotechnology in corneal neovascularization therapy--a reviewUnderstanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions.Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes.Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.Corneal Endothelial Cell Integrity in Precut Human Donor Corneas Enhanced by Autocrine Vasoactive Intestinal Peptide.Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications.Proangiogenic Function of T Cells in Corneal Transplantation.Management of High-risk Corneal Transplantation.Current and Upcoming Therapies for Ocular Surface Chemical Injuries.Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment.Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization.Recent drug therapies for corneal neovascularization.Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.Therapeutic approaches for corneal neovascularization.Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.New Therapeutic Perceptions in a Patient with Complicated Herpes Simplex Virus 1 Keratitis: A Case Report and Review of the Literature.Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function.Update on the Management of High-Risk Penetrating Keratoplasty.Angiogenesis and lymphangiogenesis in corneal transplantation-A review.Selective IKK2 inhibitor IMD0354 disrupts NF-κB signaling to suppress corneal inflammation and angiogenesis.Topical Timolol Inhibits Corneal Neovascularization in Rabbits.Prox1-GFP/Flt1-DsRed transgenic mice: an animal model for simultaneous live imaging of angiogenesis and lymphangiogenesis.Kinetics of Angiogenic Responses in Corneal Transplantation.Two-photon microscopy of a Flt1 peptide-hyaluronate conjugate.Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization.The effect of topical doxycycline on corneal neovascularization.A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study.Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.Long-term outcomes of Fine Needle Diathermy for established corneal neovascularisation
P2860
Q26776229-146BF664-AC6A-4457-B8C9-3217A39896DCQ28544711-FECBAD6D-6B50-4ACB-9281-9370658B17CEQ36145217-002F5A1A-076D-4764-87D4-46A45614468BQ36342984-75F69BD8-7C76-4478-A848-B759C7CFB78DQ36696450-D58562A6-1AF4-49FF-BD15-235C7DAE5CF6Q36808641-7B614897-6FB2-4FA7-B203-15AD04CB738EQ37218666-8C934677-1B64-489C-A767-DECE85B5A7FAQ37329315-45976F5F-DBF9-4F69-B2CC-95C8A32CADCEQ37644799-49D75991-A7B1-4927-80A3-59EDFD20AFA3Q37677778-956F04A9-CF13-49F9-95A0-87D4187E21C8Q38323786-44864CE4-E2E5-4CC8-82C5-3CECA0D01899Q38753891-09D08836-1D97-43B5-B4D5-134C722B1F2AQ38778422-E7346498-5355-43CD-968B-22D82799DA4BQ38819339-6E31DA66-0A73-40D7-8420-DEAB416DBFADQ38958273-35BBF97A-9165-4668-8C01-ED055AECC29EQ39023803-510DA38C-500B-4255-89F5-14E23DD9B510Q39295602-EA0B4296-32EE-4DC3-A0DA-5A1705DE9569Q41660636-5C453EB4-7286-4986-A48E-A46B411D6F46Q47143268-665EF576-6ABA-4C4D-A5A6-E6AB25D5E72CQ47162407-898D7B6A-1F18-49EE-AD6C-97B6188AACE9Q47560326-F5DB270F-8AE4-4E8A-80ED-8292993FA898Q47562176-A52F0BF0-A3DD-4D34-B2DD-E89ADA5D4879Q47620917-0E5F9B2F-1C4D-43E2-B57A-4F8B1EE5510CQ47759308-5D0CED28-9F76-46B3-9522-9C4FE53EDE40Q48248176-1522D3D9-67CC-4228-B3EE-83787D3BA4D9Q49211752-672BAD63-0A77-4762-945D-F6466B0666FFQ50506414-9F579136-5BF8-43ED-9402-9A0B20C03445Q50968165-D2BE9CC9-D1ED-4064-A8C8-0A58B4316114Q51827148-6B7FDF80-331C-46FD-BA91-B62659DD7574Q52609710-A20B70BB-8ED3-4367-AC5D-6CEB01318566Q53097781-A815572A-9382-4BD9-A3F9-32E1E5316B3BQ53516902-2DEC5A51-20B2-403B-9480-1BED7006E95DQ54626084-E6409DAF-23C8-4137-9614-F4A093951C5FQ58990047-12DFC55B-A3CE-4D52-B25D-CDAD84DA297D
P2860
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@ast
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@en
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@nl
type
label
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@ast
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@en
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@nl
prefLabel
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@ast
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@en
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@nl
P2093
P2860
P3181
P1433
P1476
Corneal neovascularization and ...... ntis) vs bevacizumab (Avastin)
@en
P2093
Mohammad H Dastjerdi
Sheng-Fu Cheng
William Stevenson
P2860
P3181
P356
10.1016/J.JTOS.2012.01.005
P407
P577
2012-01-25T00:00:00Z